BR112014019672A2 - - Google Patents

Info

Publication number
BR112014019672A2
BR112014019672A2 BR112014019672A BR112014019672A BR112014019672A2 BR 112014019672 A2 BR112014019672 A2 BR 112014019672A2 BR 112014019672 A BR112014019672 A BR 112014019672A BR 112014019672 A BR112014019672 A BR 112014019672A BR 112014019672 A2 BR112014019672 A2 BR 112014019672A2
Authority
BR
Brazil
Application number
BR112014019672A
Other languages
Portuguese (pt)
Other versions
BR112014019672A8 (pt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48946098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014019672(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR112014019672A2 publication Critical patent/BR112014019672A2/pt
Publication of BR112014019672A8 publication Critical patent/BR112014019672A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002—Carbocyclic rings fused
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112014019672A 2012-02-15 2013-02-13 Triterpenoides de c-3 cicloalquenila com atividade inibidora de maturação de hiv BR112014019672A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261599040P 2012-02-15 2012-02-15
US13/760,726 US8906889B2 (en) 2012-02-15 2013-02-06 C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
PCT/US2013/025897 WO2013123019A1 (en) 2012-02-15 2013-02-13 C-3 cycloalkenyl triterpenoids with hiv maturation inhibitory activity

Publications (2)

Publication Number Publication Date
BR112014019672A2 true BR112014019672A2 (enExample) 2017-06-20
BR112014019672A8 BR112014019672A8 (pt) 2017-07-11

Family

ID=48946098

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014019672A BR112014019672A8 (pt) 2012-02-15 2013-02-13 Triterpenoides de c-3 cicloalquenila com atividade inibidora de maturação de hiv

Country Status (26)

Country Link
US (1) US8906889B2 (enExample)
EP (1) EP2814834B1 (enExample)
JP (1) JP6155285B2 (enExample)
KR (1) KR20140123584A (enExample)
CN (2) CN104220451B (enExample)
AR (1) AR089996A1 (enExample)
AU (1) AU2013221725B2 (enExample)
BR (1) BR112014019672A8 (enExample)
CA (1) CA2864656A1 (enExample)
CL (1) CL2014002141A1 (enExample)
CO (1) CO7061077A2 (enExample)
EA (1) EA024361B1 (enExample)
ES (1) ES2656984T3 (enExample)
HK (1) HK1204608A1 (enExample)
IL (1) IL234077A (enExample)
MX (1) MX2014009235A (enExample)
MY (1) MY166793A (enExample)
NZ (1) NZ631408A (enExample)
PE (1) PE20142315A1 (enExample)
PH (1) PH12014501816A1 (enExample)
PT (1) PT2814834T (enExample)
SG (1) SG11201404748XA (enExample)
TW (1) TW201336863A (enExample)
UY (1) UY34627A (enExample)
WO (1) WO2013123019A1 (enExample)
ZA (1) ZA201406724B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
MX2015010003A (es) 2013-02-06 2015-10-30 Squibb Bristol Myers Co Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).
MX374543B (es) * 2014-04-11 2025-03-06 Viiv Healthcare Uk No 4 Ltd Triterpenoides con actividad inhibidora de la maduración del virus de inmunodeficiencia humana, sustituidos en la posición 3 con un anillo no aromático que lleva un sustituyente haloalquilo.
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
KR20170087478A (ko) * 2014-11-14 2017-07-28 비브 헬스케어 유케이 (넘버5) 리미티드 옥소루펜 유도체
WO2016077572A1 (en) * 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Extended betulinic acid analogs
AU2015346311A1 (en) 2014-11-14 2017-06-08 Viiv Healthcare UK (No5) Limited C17-aryl substituted betulinic acid analogs
AU2016248235A1 (en) * 2015-04-14 2017-10-19 Viiv Healthcare Uk (No 4) Limited Crystalline forms of modified triterpenoid hydrochloride salts with HIV maturation inhibitor activity
BR112018001484A2 (pt) 2015-07-28 2018-09-11 Glaxosmithkline Ip No 2 Ltd “composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de uma composição farmacêutica
RU2018105352A (ru) 2015-07-28 2019-08-29 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Производные бетулина для предупреждения или лечения ВИЧ-инфекций
CA2998828A1 (en) 2015-09-24 2017-03-30 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
US20190023733A1 (en) * 2016-01-20 2019-01-24 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN106905264B (zh) * 2017-04-12 2019-06-07 连云港杰瑞药业有限公司 一种合成阿扎拉韦中间体的方法
CN111093673B (zh) 2017-09-13 2025-07-29 艾蒙有限责任公司 熊果酸吗啉盐和熊果酸二乙醇胺盐
JP7436385B2 (ja) 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Ｈｉｖ成熟阻害活性を有する化合物
CN109705189B (zh) * 2018-12-29 2020-06-05 中国医学科学院药用植物研究所 具有式i所示结构的三萜衍生物及其制备方法和应用
PT3924361T (pt) 2019-02-11 2023-12-12 Hetero Labs Ltd Novos derivados de triterpeno como inibidores do vih
WO2020229398A1 (de) 2019-05-14 2020-11-19 Bayer Aktiengesellschaft (1-alkenyl)-substituierte pyrazole und triazole als schädlingsbekämpfungsmittel

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US20050014730A1 (en) 2003-04-02 2005-01-20 Carlson Robert M. Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
JP2007529544A (ja) 2004-03-17 2007-10-25 パナコス ファーマシューティカルズ， インコーポレイテッド ３−ｏ−（３’，３’−ジメチルスクシニル）ベツリン酸の製薬的な塩
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
EP2178376A4 (en) 2007-08-03 2011-12-14 Advanced Life Sciences Inc LUPANIC TRITERPENOIDS MODIFIED IN 30-POSITION AND ITS ANALOG
CN101981047A (zh) * 2008-01-03 2011-02-23 Viro化学制药公司 新的羽扇烷衍生物
JP2011511812A (ja) * 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規１７βルパン誘導体
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
EP2513098B1 (en) 2009-12-17 2016-11-09 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
DK2576586T3 (en) * 2010-06-04 2015-11-23 Bristol Myers Squibb Co C-28 AMINES OF MODIFIED C-3-BETULIN ACID DERIVATIVES AS ANTI-HUMIDITY INHIBITORS
CA2801487C (en) 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
PH12013500011A1 (en) 2010-07-02 2013-02-18 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat aids
SI2670764T1 (sl) 2011-01-31 2016-03-31 Bristol-Myers Squibb Company C-28 amini derivatov c-3 modificirane betulinske kisline inhibitorjev zorenja hiv
MA34909B1 (fr) * 2011-01-31 2014-02-01 Bristol Myers Squibb Co Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih
SG11201400331WA (en) * 2011-09-21 2014-08-28 Bristol Myers Squibb Co Novel betulinic acid derivatives with antiviral activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
MX2015010003A (es) * 2013-02-06 2015-10-30 Squibb Bristol Myers Co Triterpenoides c-19 modificados, con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana (vih).

Also Published As

Publication number Publication date
SG11201404748XA (en) 2014-09-26
JP2015510515A (ja) 2015-04-09
NZ631408A (en) 2015-06-26
EA201491531A1 (ru) 2014-11-28
HK1204608A1 (en) 2015-11-27
WO2013123019A1 (en) 2013-08-22
CL2014002141A1 (es) 2014-10-03
BR112014019672A8 (pt) 2017-07-11
US20130210787A1 (en) 2013-08-15
US8906889B2 (en) 2014-12-09
CO7061077A2 (es) 2014-09-19
JP6155285B2 (ja) 2017-06-28
CA2864656A1 (en) 2013-08-22
CN106046106A (zh) 2016-10-26
CN104220451A (zh) 2014-12-17
MX2014009235A (es) 2014-11-10
EA024361B1 (ru) 2016-09-30
PH12014501816A1 (en) 2014-11-17
IL234077A0 (en) 2014-09-30
UY34627A (es) 2013-09-02
PE20142315A1 (es) 2015-01-16
ES2656984T3 (es) 2018-03-01
MY166793A (en) 2018-07-23
KR20140123584A (ko) 2014-10-22
ZA201406724B (en) 2016-08-31
TW201336863A (zh) 2013-09-16
EP2814834A1 (en) 2014-12-24
AR089996A1 (es) 2014-10-01
AU2013221725A1 (en) 2014-10-02
IL234077A (en) 2016-11-30
AU2013221725B2 (en) 2016-10-27
EP2814834B1 (en) 2017-09-13
PT2814834T (pt) 2017-12-06
CN104220451B (zh) 2016-06-29

Similar Documents

Publication Publication Date Title
BR112014020075A2 (enExample)
BR112014017614A2 (enExample)
BR112014025395A2 (enExample)
BR112014017625A2 (enExample)
BR112014017659A2 (enExample)
BR112014017592A2 (enExample)
BR112014019393A2 (enExample)
BR112014017646A2 (enExample)
BR112014017607A2 (enExample)
BR112014022670A2 (enExample)
BR112014018017A2 (enExample)
BR112013027865A2 (enExample)
BR112014019493A2 (enExample)
BR112014017609A2 (enExample)
BR112014024017A2 (enExample)
BR112014019672A2 (enExample)
BR112014017644A2 (enExample)
BR112014019584A2 (enExample)
BR112014017588A2 (enExample)
BR112014017618A2 (enExample)
BR112014017647A2 (enExample)
BR112015014795A2 (enExample)
BR112014013184A8 (enExample)
BR112014017623A2 (enExample)
BR112014018440A2 (enExample)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: VIIV HEALTHCARE UK (NO.5) LIMITED (GB)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements